E Nadal

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies
    E Nadal
    Haematology Department, Hammersmith Hospital, Imperial College, London, UK
    Int J Clin Pract 58:511-6. 2004
  2. ncbi request reprint Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib
    S Avery
    Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Leuk Res 28:S75-7. 2004

Collaborators

  • E Olavarria
  • S Avery
  • F Brito Babapulle
  • T Vulliamy
  • D Marin
  • J F Apperley
  • J Kaeda
  • J M Goldman

Detail Information

Publications2

  1. ncbi request reprint Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies
    E Nadal
    Haematology Department, Hammersmith Hospital, Imperial College, London, UK
    Int J Clin Pract 58:511-6. 2004
    ..Imatinib is an example of how a better understanding of the pathogenetic mechanisms of a neoplastic disease can lead to the development of a molecular-targeted therapy...
  2. ncbi request reprint Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib
    S Avery
    Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Leuk Res 28:S75-7. 2004
    ..The case highlights the need for molecular monitoring of responders and the need to develop strategies for reducing to a minimum or totally eradicating leukemia cells...